Maynard Um
-
-
-
-
-
-
-
Deutsche Bank on Legend Biotech Corp. (LEGN): 'Most incremental, in our view, LEGN will share first patient data for its in-vivo CAR T program by YE26'
-
-
-
-
-
-
-
Legend Biotech Corp. (LEGN) PT Lowered to $60 at H.C. Wainwright
-
-
-
-
-
-
-
Legend Biotech Corp. (LEGN) PT Raised to $77 at RBC Capital on Growth Potential
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
-
-
-
-
-
-
Legend Biotech (LEGN) Misses Q1 EPS by 6c
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
-
-
-
-
-
-
Goldman Sachs Reiterates Buy Rating on Legend Biotech Corp. (LEGN)
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

